Details for New Drug Application (NDA): 020936

✉ Email this page to a colleague

NDA 020936 describes PAXIL CR, which is a drug marketed by Apotex and is included in one NDA. It is available from one supplier. Additional details are available on the PAXIL CR profile page.

The generic ingredient in PAXIL CR is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.

Summary for 020936

Tradename:	PAXIL CR
Applicant:	Apotex
Ingredient:	paroxetine hydrochloride
Patents:	0

Pharmacology for NDA: 020936

Mechanism of Action	Serotonin Uptake Inhibitors

Suppliers and Packaging for NDA: 020936

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936	NDA AUTHORIZED GENERIC	Apotex Corp	60505-1316	60505-1316-3	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (60505-1316-3)
PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936	NDA AUTHORIZED GENERIC	Apotex Corp	60505-1317	60505-1317-3	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (60505-1317-3)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 12.5MG BASE
Approval Date:	Feb 16, 1999	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 25MG BASE
Approval Date:	Feb 16, 1999	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	EQ 37.5MG BASE
Approval Date:	Dec 6, 2000	TE:	AB	RLD:	Yes

Expired US Patents for NDA 020936

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999	4,839,177*PED	⤷ Subscribe
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999	6,133,289*PED	⤷ Subscribe
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-003	Dec 6, 2000	6,133,289*PED	⤷ Subscribe
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-003	Dec 6, 2000	5,789,449*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.